A No-Nonsense Look at Canopy Growth Since Its IPO

What does it really cost to run Canopy Growth Corp. (TSX:WEED)(NYSE:CGC)?

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

Even if you aren’t a big investor, chances are you’re still aware that the marijuana industry has been the hottest thing since the internet on the stock market.

For the last two or three years, investors have gained (and lost) a lot betting on these stocks, with Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) emerging as one of the top players in this young industry.

Yet even as stocks go up and down, there is still a lot of opportunity to grow in the future. Wall Street estimates that worldwide, cannabis sales could be worth up to US$75 billion a decade from now.

Millennials love marijuana

Part of the reason stocks like Canopy have done so well is that a new wave of investors have entered the market. In fact, Canopy is one of the most popular marijuana stocks held by millennials, based on the 20 most widely held stocks on Robinhood.

To give you an idea of how crazy this is, that means more people own Canopy than other stocks like Facebook or Amazon.

What millennials like is two-fold: its powerhouse of production and global expansion. While the company tends to keep its exact numbers close to its chest, Canopy has been acquiring and expanding at a rapid pace, setting itself up so that estimates are the company can produce well over 500,000 kilograms of marijuana per year.

It’s been no secret that the company has also looked to the United States to further its expansion. Canopy has been acquiring licenses to produce hemp across the country, creating partnerships along the way to set themselves up for when marijuana is likely legalized south of the border.

But beyond the U.S., Canopy has a presence in about 16 countries as of writing, meaning it’s not just banking on North America to make a buck. As I’ve mentioned, there is a huge global opportunity in the works, and Canopy wants a piece of the action.

Whether it’s through medical marijuana, hemp-based products, edibles, makeup, you name it, Canopy is taking over the marijuana market in pretty much any way that exists.

So why has the stock been dropping?

A fine balance

Since its initial public offering (IPO) Canopy has skyrocketed from $0.75 per share in July, 2010 to around $70 per share last summer before coming down after legalization.

It then rebounded in the new year and almost reached all-highs before slumping again to where it trades now at $46.61 per share. But still, if we’re to look at where it all began, that’s an increase of 6,115%!

The slump comes down to the quarterly reports. Across the board, marijuana stocks have been reporting losses, and yet still spending shareholder and partnership dollars to expand its cannabis empire.

Things recently came to a head for Canopy, where after reporting a loss of $323.4 million, founder and CEO Bruce Linton was fired.

Basically, shareholders have to decide if they’re willing to wait for U.S. legalization, ramped up production, and the slew of other projects the company has in store. That’s because this company is looking at that decade-ahead number, and not the numbers hitting the earnings report right now.

Those projects cost money, but those costs only come once. Once you take those costs out, things look a bit different.

So let’s look at Canopy’s bottom line. In its most recent quarterly report ending Mar. 31, 2019, Canopy reported $68.9 million in gross recreational sales, $13.4 million in medical sales, and net revenue of $94.1 million for the quarter.

Its gross profit was $14.97 million for the quarter, which led to a gross margin of 16%, down from 34% the same time last year, and 22% in Q3.

Much of this loss came down to one-time costs, according to Canopy, including $24 million operating expenses for facilities that either aren’t cultivating, not yet harvesting, or under-utilized; a weather event; and other “one-time activities” that it doesn’t foresee affecting future operations.

However, it does foresee future costs related to ramping up production during its “start-up phase.”

So if we cut out those one-time costs, we can get to what investors should really be looking at. With gross profit at $14.97 million, investors should just look at operating expenses of $253.5 million.

So if we take out all those one-time costs, that means the company’s total loss for the quarter was $238.5 million. While it’s still high, it’s about $100 million less than the $323.4 million shown on the quarterly report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth. David Gardner owns shares of Amazon and Facebook. Tom Gardner owns shares of Facebook. The Motley Fool owns shares of Amazon and Facebook. Facebook is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »